Show Search Form
human indexable | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
published | |||||||||||
registered interest | |||||||||||
answer date | |||||||||||
date | |||||||||||
date tabled | |||||||||||
ddp created | |||||||||||
answering body |
|
||||||||||
question status | Tabled | ||||||||||
answering dept id | 21 | ||||||||||
answering dept short name | Northern Ireland | ||||||||||
answering dept sort name | Northern Ireland | ||||||||||
ddp modified |
|
||||||||||
hansard heading | Cancer: Northern Ireland | ||||||||||
house id | 1 | ||||||||||
identifier | 188109 | ||||||||||
legislature |
|
||||||||||
parliament number | 57 | ||||||||||
question first answered |
|
||||||||||
question text | To ask the Secretary of State for Northern Ireland, with reference to the Department of Health in Northern Ireland (DHNI)’s press release entitled Department Announces Improved Access to New Drugs, published on 12 September 2018, what discussions she has had with the DHNI on the timeline for providing access to medicines approved for use through the Cancer Drug Fund in England; and if she will make a statement. | ||||||||||
session |
|
||||||||||
session number | 1 | ||||||||||
tabling member constituency | Strangford | ||||||||||
tabling member printed |
|
||||||||||
title | House of Commons Tabled Parliamentary Question 2017/19 188109 | ||||||||||
type |
|
||||||||||
uin | 188109 | ||||||||||
version | 1 | ||||||||||
written parliamentary question type | Ordinary | ||||||||||
answer | answer | ||||||||||
creator |
|
||||||||||
publisher |
|
||||||||||
tabling member |
|